Lantern Pharma (LTRN) Q2 FY26 earnings call

Lantern Pharma is undergoing a significant structural transformation, spinning out its AI engine into a new company, Open Medicine AI, to unlock value and accelerate its commercialization. Concurrently, the company continues to advance its clinical pipeline with promising data from the LP-300 HARMONIC trial, regulatory clearances for LP-184, and progress in its pediatric oncology programs, all while maintaining disciplined cost management despite increased net losses driven by non-cash warrant expenses.